Published in Biomark Med on October 01, 2011
Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a). J Am Coll Cardiol (2014) 2.28
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Genetic variants in PLG, LPA, and SIGLEC 14 as well as smoking contribute to plasma plasminogen levels. Blood (2014) 1.51
Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol (2015) 1.47
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res (2012) 1.18
Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Curr Opin Pharmacol (2013) 1.06
Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol (2012) 1.04
Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). J Lipid Res (2013) 1.04
Oxidation-specific biomarkers and risk of peripheral artery disease. J Am Coll Cardiol (2013) 0.96
MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. J Lipid Res (2013) 0.95
Biological relevance of inflammation and oxidative stress in the pathogenesis of arterial diseases. Am J Pathol (2013) 0.92
Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol (2015) 0.92
Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. Circulation (2016) 0.91
Oxidative lipidomics coming of age: advances in analysis of oxidized phospholipids in physiology and pathology. Antioxid Redox Signal (2015) 0.88
Oxidation-specific epitopes as targets for biotheranostic applications in humans: biomarkers, molecular imaging and therapeutics. Curr Opin Lipidol (2013) 0.83
Oxidized lipoprotein(a) and cardio-ankle vascular index (CAVI) in hypertensive subjects. Heart Vessels (2012) 0.82
Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study. Arterioscler Thromb Vasc Biol (2015) 0.82
Atherosclerotic cardiovascular disease: a review of initiators and protective factors. Inflammopharmacology (2016) 0.81
Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res (2012) 0.81
Protein lipoxidation: Detection strategies and challenges. Redox Biol (2015) 0.79
Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions. J Cardiovasc Transl Res (2014) 0.79
Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res (2015) 0.79
Lipoprotein (a) upregulates ABCA1 in liver cells via scavenger receptor-B1 through its oxidized phospholipids. J Lipid Res (2015) 0.78
Lipoprotein(a) and Arterial Stiffness Parameters. Pulse (Basel) (2015) 0.77
Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc (2015) 0.76
Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk. Curr Opin Endocrinol Diabetes Obes (2016) 0.76
The LPA Gene, Ethnicity, and Cardiovascular Events. Circulation (2016) 0.75
Human IgM Antibodies to Malondialdehyde Conjugated With Albumin Are Negatively Associated With Cardiovascular Disease Among 60-Year-Olds. J Am Heart Assoc (2016) 0.75
Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. J Lipid Res (2016) 0.75
Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. J Thromb Thrombolysis (2016) 0.75
Influence on Adiposity and Atherogenic Lipaemia of Fatty Meals and Snacks in Daily Life. J Lipids (2017) 0.75
Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease: The Copenhagen General Population Study. Arterioscler Thromb Vasc Biol (2017) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med (1989) 15.67
Atherosclerosis. the road ahead. Cell (2001) 11.88
Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol (2011) 8.75
Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11
Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet (1992) 7.09
Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell (2008) 6.37
Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci U S A (1989) 5.65
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 4.47
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med (1992) 3.52
Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest (2000) 3.51
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med (1990) 3.17
ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb (1994) 3.11
A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab (2006) 3.06
Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation (2000) 3.05
Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation (2001) 3.03
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci U S A (1999) 2.85
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest (1999) 2.81
Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J Exp Med (1982) 2.79
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation (2008) 2.62
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol (2011) 2.60
Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation (1998) 2.32
The lipid whisker model of the structure of oxidized cell membranes. J Biol Chem (2007) 2.31
Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA (2008) 2.28
Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA (1986) 2.08
Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation (2007) 2.07
Generation and biological activities of oxidized phospholipids. Antioxid Redox Signal (2010) 2.04
Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med (2008) 2.01
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation (2004) 1.97
Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis (1986) 1.81
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res (2008) 1.79
Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin Chem (2003) 1.74
Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem (2001) 1.67
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler Thromb Vasc Biol (2002) 1.64
Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res (2009) 1.63
Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol (2004) 1.58
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest (2008) 1.54
Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol (2001) 1.52
The role of oxidized phospholipids in atherosclerosis. J Lipid Res (2008) 1.51
The role of innate immunity in atherogenesis. J Lipid Res (2008) 1.50
Lipoprotein-associated and secreted phospholipases A₂ in cardiovascular disease: roles as biological effectors and biomarkers. Circulation (2010) 1.44
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity (2005) 1.40
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol (2010) 1.34
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol (2008) 1.27
Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet (1997) 1.27
Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol (2011) 1.23
Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol (2006) 1.21
Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin Chem (1986) 1.19
Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation (2009) 1.16
Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential pro-inflammatory properties to human apolipoprotein(a). J Biol Chem (2003) 1.13
Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler Thromb Vasc Biol (2006) 1.10
Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med (2009) 1.02
Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol (2008) 1.01
Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr Opin Lipidol (2006) 1.01
Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension (1999) 0.98
Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol (2010) 0.95
Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res (2010) 0.95
Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J Am Coll Cardiol (2010) 0.93
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol (2006) 0.92
Subendothelial retention of lipoprotein (a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J Clin Invest (1997) 0.91
The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis (2009) 0.82
Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. Am J Cardiol (1999) 0.82
Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am Heart J (2005) 0.80
Role of lipoprotein(a) in cardiovascular disease current and future perspectives. J Am Coll Cardiol (2008) 0.80
Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis. Blood Purif (2007) 0.77
A comprehensive classification system for lipids. J Lipid Res (2005) 6.52
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 4.47
Innate and acquired immunity in atherogenesis. Nat Med (2002) 4.22
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med (2005) 4.16
Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care (2008) 3.65
Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab (2010) 3.29
Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest (2004) 3.23
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol (2008) 3.15
Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res (2011) 2.89
Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation (2002) 2.80
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest (2009) 2.75
Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem (2002) 2.66
Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature (2011) 2.64
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest (2004) 2.56
Liver heparan sulfate proteoglycans mediate clearance of triglyceride-rich lipoproteins independently of LDL receptor family members. J Clin Invest (2007) 2.53
Critical role of IL-17RA in immunopathology of influenza infection. J Immunol (2009) 2.51
Deficiency of cathepsin S reduces atherosclerosis in LDL receptor-deficient mice. J Clin Invest (2003) 2.48
Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler Thromb Vasc Biol (2005) 2.41
Regulated accumulation of desmosterol integrates macrophage lipid metabolism and inflammatory responses. Cell (2012) 2.38
Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol (2008) 2.26
C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci U S A (2002) 2.20
Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. J Am Coll Cardiol (2013) 2.18
Apoptotic cells with oxidation-specific epitopes are immunogenic and proinflammatory. J Exp Med (2004) 2.10
Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med (2014) 2.06
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation (2004) 1.97
Oxidative damage in multiple sclerosis lesions. Brain (2011) 1.95
Evidence mandating earlier and more aggressive treatment of hypercholesterolemia. Circulation (2008) 1.91
Vascular lipid accumulation, lipoprotein oxidation, and macrophage lipid uptake in hypercholesterolemic zebrafish. Circ Res (2009) 1.89
Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum (2005) 1.89
T-bet deficiency reduces atherosclerosis and alters plaque antigen-specific immune responses. Proc Natl Acad Sci U S A (2005) 1.82
Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol (2007) 1.79
A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res (2008) 1.79
Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation (2006) 1.77
Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol (2009) 1.77
Antioxidant vitamin supplements and cardiovascular disease. Circulation (2004) 1.76
Critical role of macrophage 12/15-lipoxygenase for atherosclerosis in apolipoprotein E-deficient mice. Circulation (2004) 1.70
Reduced in vivo aortic uptake of radiolabeled oxidation-specific antibodies reflects changes in plaque composition consistent with plaque stabilization. Arterioscler Thromb Vasc Biol (2004) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem (2001) 1.67
Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol (2003) 1.66
The role of natural antibodies in atherogenesis. J Lipid Res (2005) 1.65
Macrophage apoptosis exerts divergent effects on atherogenesis as a function of lesion stage. Circulation (2009) 1.65
Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res (2009) 1.63
Oxidized membrane vesicles and blebs from apoptotic cells contain biologically active oxidized phospholipids that induce monocyte-endothelial interactions. Arterioscler Thromb Vasc Biol (2002) 1.62
Helix-loop-helix factor inhibitor of differentiation 3 regulates interleukin-5 expression and B-1a B cell proliferation. Arterioscler Thromb Vasc Biol (2013) 1.61
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Phosphocholine as a pattern recognition ligand for CD36. J Lipid Res (2005) 1.59
Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol (2004) 1.58
Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol (2010) 1.56
Syndecan-1 is the primary heparan sulfate proteoglycan mediating hepatic clearance of triglyceride-rich lipoproteins in mice. J Clin Invest (2009) 1.56
Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: pathophysiological basis and endovascular treatment. Catheter Cardiovasc Interv (2004) 1.56
Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol (2012) 1.55
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation (2008) 1.55
Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J Clin Invest (2008) 1.54
The role of oxidized phospholipids in atherosclerosis. J Lipid Res (2008) 1.51
Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation. Arterioscler Thromb Vasc Biol (2002) 1.51
The role of innate immunity in atherogenesis. J Lipid Res (2008) 1.50
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation (2003) 1.49
Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis. JACC Cardiovasc Interv (2008) 1.47
Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a "stent"? J Am Coll Cardiol (2004) 1.46
Pioglitazone modulates vascular inflammation in atherosclerotic rabbits noninvasive assessment with FDG-PET-CT and dynamic contrast-enhanced MR imaging. JACC Cardiovasc Imaging (2011) 1.46
Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol (2011) 1.45
Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem (2001) 1.44
Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation (2002) 1.43
Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J Clin Invest (2013) 1.43
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation (2004) 1.43
Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem (2008) 1.40
ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res (2010) 1.37
Influence of C3 deficiency on atherosclerosis. Circulation (2002) 1.37
The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol (2008) 1.36
The autoreactivity of anti-phosphorylcholine antibodies for atherosclerosis-associated neo-antigens and apoptotic cells. J Immunol (2003) 1.36
Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation. J Biol Chem (2010) 1.35
Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol (2010) 1.34
A diet-induced hypercholesterolemic murine model to study atherogenesis without obesity and metabolic syndrome. Arterioscler Thromb Vasc Biol (2007) 1.31
High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation. Arterioscler Thromb Vasc Biol (2004) 1.30
Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. J Am Coll Cardiol (2012) 1.30
In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. J Clin Invest (2011) 1.27
The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr Opin Lipidol (2008) 1.27
Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol (2003) 1.26
The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell Metab (2012) 1.24